[FG] Krisai Philipp

SERVE was a double-blind, randomized, placebo-controlled, multicenter superiority trial (NCT03049540) conducted in Switzerland. The study enrolled 100 adults with a systemic right ventricle (sRV), comparing tadalafil 20 mg once daily versus placebo over a 3-year period. More information: www.sacher-registry.com/serve

The primary endpoint was the change in right ventricular end-systolic volume (RVESV); secondary endpoints included changes in right ventricular ejection fraction, NT-proBNP levels, and exercise capacity.

I was involved as a Co-Investigator at the Basel and Bern center, contributing to patient enrollment, follow-up, and data analysis.

Related peer-reviewed publications are available at:

👉 https://www.sacher-registry.com/serve/publications/accepted-manuscripts/

SACHER is a prospective national registry for adults with congenital heart disease (ACHD) in Switzerland. It systematically collects clinical, procedural, and long-term outcome data from all major Swiss ACHD centers. The aim is to support observational research, quality benchmarking, and evidence generation for this growing patient population. More information is available at: www.sacher-registry.com.

I am involved as a Co-Investigator, contributing to patient enrollment, data quality control, and scientific analysis at the Basel center. The registry serves as a platform for multiple subprojects and collaborations, including EPOCH and EPOCH-ASO.

A list of accepted peer-reviewed publications arising from SACHER can be found here:

👉 https://www.sacher-registry.com/sacher/publications/accepted-manuscripts/